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Summary. Giant cell tumour of bone (GCT) is a benign 
primary neoplasm of a bone characterised by distinctive 
clinical, radiological and pathological features. Females 
are slightly more often affected than males, and the 
majority of patients present between the ages of 20 and 
50. GCT is locally aggressive and produces expansive 
and lytic lesions, most commonly in the epiphyses of 
long tubular bones. Histologically, it is composed of oval 
and spindle mononuclear cells, uniformly distributed 
amongst which are large multinucleated osteoclast-like 
giant cells. Although the term "Giant Cell Tumour" (and 
the erroneous historical term 'osteoclastoma') may 
imply that it is the multinucleated giant cells which are 
responsible for the proliferative capacity of the tumour, 
there is evidence that the stromal-like cells, the major 
component of the mononuclear celi population, represent 
the true neoplastic component of the neoplasm. The 
diagnosis and management of conventional GCT are 
often challenging and there is considerable current 
interest in its pathobiology. The precise histogenesis of 
GCT and the nature of its varying cellular constituents 
have remained a matter of some controversy. Factors 
influencing the clinical course and biological aggression 
of GCT are also unclear. In this selective review, the 
clinicopathological characteristics of GCT are 
summarised and current areas of interest in the study of 
the neoplasm are presented and discussed. Lastly, a 
hypothetical model of the mechanism of histogenesis 
and the biological behaviour of GCT is presented. 
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lntroduction 
Giant cell tumour of bone (GCT), which has also 
been referred to as 'conventional giant cell tumour of 
boney or 'osteoclastoma' (Schajowicz, 1994), is  
classified according to the WHO as "an aggressive 
tumour, characterised by richly vascularised tissue 
consisting of rather plump spindle-shaped or ovoid cells 
of osteoclast type, which are uniformly distributed 
throughout the tumour tissue" (Schajowicz, 1994). 
Although the term "Giant Cell Tumour" and 
"osteoclastoma" may imply that it is the multinucleated 
giant cells which are responsible for the proliferative 
capacity of the neoplasm, there is evidence that the 
stromal-like cells, the major component of the 
mononuclear cell population, represent the true 
neoplastic component. The diagnosis and management 
of conventional GCT are often challenging and there is 
considerable current interest in the pathobiology of 
GCT. 
Although bone destruction is a characteristic feature 
of GCT, there is, as yet, no evidence that the neoplastic 
cells are capable of bone resorption. Instead, it appears 
that the neoplastic cells of GCT act by promoting bone 
resorption. In fact, this interplay between the neoplastic 
cells and the multinucleate osteoclast-like giant cells 
found in GCT has been considered as a model of the 
cellular interactions that occur during bone resorption in 
both primary and metastatic neoplasms (Grano et al., 
1994; Robinson et al., 1994; Zambonin-Zallone et al., 
1995). 
In this selective review, the clinicopathological 
characteristics of GCT will be briefly summarised and 
current areas of interest in the study of the neoplasm will 
be presented and discussed. Theories of the histogenesis 
of GCT, the role of cytokines and steroid hormones in its 
development and behaviour and its karyotypic profile 
will be reviewed. The role of the neoplastic cells of GCT 
in promoting osteoclastogenesis and osteoclastic bone 
absorption will also be discussed, as this is an area of 
particular current interest. 
Pathobiology of GCT 
Clinicopathological characteristics of GCT 
GCTs occur most often in skeletally mature 
individuals (Huvos, 1991). Over 80% of GCTs are 
diagnosed in patients over the age of 20, with the third to 
fifth decades of life being the most commonly affected 
(Robbins et al., 1994). The incidence of GCT is slightly 
higher in women than men (Leu et al., 1986; Huvos, 
1991; Robbins et al., 1994; Schajowicz, 1994; Unni, 
1996), the ratio being 3:2 (Huvos, 1991; Schajowicz, 
1994). The vast majority of GCTs arise 'de novo', and 
are solitary and unifocal. 'Multifocal giant cell tumour 
of bone' is extremely rare, usually occurs in the 
epiphyses of long bones at two to three anatomic sites 
and must be distinguished from the osseus lesions of 
hyperparathyroidism and malignancies rich in giant cells 
(Huvos, 1991; Robbins et al., 1994; Schajowicz, 1994). 
Giant cell tumour of bone has been reported in 
association with Paget's disease of the skeleton; however, 
its incidence in this setting is much less common than 
forms of Pagetic sarcoma such as osteosarcoma or 
malignant fibrous histocytoma (Rock et al., 1986; 
Huvos, 1991; Schajowicz, 1994). 
The incidence of GCT varies geographically and 
between races. As shown in Table 1, GCT accounts for 
5% of primary bone tumours in North America. The 
incidence of GCT is somewhat lower in Australia as 
documented by the Western Australian Bone Tumour 
Registry. The incidence of GCT is higher in Asian 
populations, in particular Chinese and Japanese, in 
whom it accounts for almost 15% of al1 primary bone 
neoplasms. 
GCT may involve virtually any bone of the skeleton, 
however, in more than 75% of cases, the tumour is found 
in the epiphyseal ends of long tubular bones 
(Schajowicz, 1994; Unni, 1996). The most frequently 
involved sites are the distal femur, proximal tibia, distal 
radius and proximal humerus (Schajowicz, 1994). 
Approximately 50% of GCTs arise around the knee 
(Robbins et al., 1994; Unni, 1996). Less common, but 
well documented sites of involvement include the 
sacrum, pelvis, spine, patella, carpa1 and tarsal bones 
(Unni, 1996). Origin in the craniofacial bones is 
exceptional, but GCTs have been detected in the 
mandible, maxilla, sphenoid and the petrous temporal 
bone sometimes in association with Paget's disease 
(Huvos, 1991; Schajowicz, 1994). Origin in the small 
bones of the hands and feet is also rare. The clinical 
signs and symptoms of GCT at presentation usually 
relate to pain andlor local swelling; pathological fracture 
Table 1. lncidence of GCT in various countries. 
COUNTRY INCIDENCE SOURCE 
occurs but is a much less common form of presentation. 
The radiological findings in conventional GCT are 
often quite characteristic. Typically GCT presents as a 
lucency, which may or may not be well defined, 
classically epiphyseal, and is subchondral and 
eccentrically located. Perilesional or intralesional 
sclerosis is uncommon and reactive new bone formation 
at the periphery of the tumour can not usually be 
appreciated radiologically. Cortical expansion and focal 
destruction may be observed, sometimes with extension 
into overlying soft tissues. These latter features form the 
basis of some radiological grading schemes, but these 
have not been shown to correlate with clinical outcome 
(Campanacci et al., 1987). Typically epiphyseal in 
origin, GCT7s can extend to involve the metaphysis, but 
on rare occasion can be solely metaphyseal in location 
and not involve the epiphysis (Unni, 1996). The articular 
cartilage is, however rarely penetrated the neoplasm, 
even in advanced cases. Joint space involvement is 
perhaps somewhat more frequent, occurring via lateral 
cortical erosion (Huvos, 1991; Schajowicz, 1994). 
Although there is a signifícant degree of variability 
in the macroscopic findings of GCT, most exhibit 
extensive soft and fleshy appearances, and range in 
colour from grey to light red to dark, reddish-brown 
(Fig. 1). The grey areas are generally firmer but are 
friable (Schajowicz, 1994). Haemorrhagic or cystic areas 
and focal fibrous septa formation are relatively common 
(Huvos, 1991). Haemorrhage occurs frequently in some 
cases, the tumour is partly replaced by large, blood-filled 
cystic cavities, traversed by thin septa, similar to those 
seen in Aneurysmal Bone Cyst (ABC). A shell of thin 
bone often surrounds the neoplasm, but this is not a 
USA 5.12% Mayo Clinic 
Australia 2.5% Bone Tumour Registiy of WA Flg. 1. Gross morphologic features of giant cell tumour of bone. 
China 14.6% Sun Yat-Sen University of Medical Sciences Bisected proximal segment of humerus with extensive soft and fleshy 
Japan 8% Japanese Orthopaedic Association tumour tissue in colour of grey, light red and dark, reddish-brown. 
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manifestation of the expanded cortex, but is  new, 
displaced cortex formed by osteoclastic resorption of the 
endosteal surface and persistent deposition of periosteal 
new bone (Huvos, 1991; Schajowicz, 1994; Unni, 1996). 
The margins or boundaries of GCT are generally not 
well defined, which rnay account for the frequency of 
local recurrence after curettage. 
The classical histological findings of GCT consist of 
a population of mononuclear cells, plump or spindle in 
appearance, interspersed amongst which are 
multinucleate osteoclast-like giant cells. The nuclei of 
the stromal and multinucleate giant cells are similar in 
appearance. The  stromal cell  population rnay be 
mitotically active, but no abnormal or atypical mitotic 
figures are found. Reactive bone rnay be formed focally, 
often at the periphery of the lesion, however no 
chondroid matrix production by the neoplastic 
population is evident. Secondary reactive changes often 
observed in GCT include haemorrhage, necrosis, 
secondary ABC formation, reactive fibrosis and 
xanthogranulomatous inflammation. 
GCT is characterised by the presence of a great 
number of large, multinucleated giant cells (Huvos, 
1991; Robbins et al., 1994;  Schajowicz, 1994), 
uniformly distributed throughout the tumour. Commonly 
referred to as 'osteoclast-like giant cells', these cells are 
well defined, with prolongations of their abundant 
cytoplasm, which is eosinophilic and homogenous, or 
sometimes, mildly granular (Schajowicz, 1994). 
Osteoclast-like giant cells,  which resemble 
osteoclasts morphologically and immunohisto- 
chemically, represent a reactive and non-neoplastic 
population of cells. They are capable of in vitro bone 
resorption and differ from multinucleate histiocytic 
syncytia of the type found in foreign body type 
reactions. The nuclei of the multinucleate giant cells in 
GCT vary in size and number, but usually they possess 
more than 20  nuclei,  sometimes even hundreds 
(Schajowicz, 1994). The multinucleate giant cells are 
scattered among a cellular background composed of 
uniform ovoid or spindle-shaped mononuclear cells that 
appear to grow in a network or 'syncytial-like' pattern 
(Robbins et al., 1994; Schajowicz, 1994). They are often 
found to be related to vascular beds and occasionally, 
stromal-like tumour cells and giant cells are present 
within blood vessels. Multinucleated giant cells seen 
within blood vessels are probably not the result of 
vascular invasion, but due to in situ formation of 
osteoclasts by the fusion of blood monocytes that have 
been activated by tumour cells (Zheng et al., 2000). 
There is little collagenous stroma in the zones of active 
tumour growth, but a dense network of reticulin fibrils 
surrounds individual cells. The vascular pattern of GCTs 
comprises an abundance of newly developed blood 
vessels lined by endothelial cells, as well as vascular 
channels lined by tumour celis. This pattern explains the 
frequent presence of abundant haemorrhage observed in 
GCT, with endocytosis of blood pigments in the 
mononuclear cells (Schajowicz, 1994). 
Although multinucleated giant cells are a prominent 
feature of GCI; their presence is not a sufficient criterion 
for diagnosing the neoplasm (Huvos, 1991). GCT rnay 
be confused with a number of osseous lesions, both 
reactive and neoplastic, which contain large numbers of 
multinucleate giant cells. There are a number of reactive 
processes which rnay contain considerable numbers of 
multinucleate giant cells, and equally, a number of 
benign and malignant osseous neoplasms rnay be giant 
cell rich. The differential diagnosis of GCT in different 
settings rnay therefore include such diverse processes as 
giant cell  reparative granuloma (Unni, 1996), 
hyperparathyroidism (Unni, 1996; Huvos, 1991), non- 
ossifying fibroma, chondroblastoma (Huvos, 1991; 
Apley and Solomon, 1993; Schajowicz, 1994; Unni, 
1996), solid areas of ABC (Roessner, 1989; Huvos, 
1991; Apley and Solomon, 1993; Schajowicz, 1994; 
Unni, 1996), and malignant lesions such as Malignant 
Fibrous Histiocytoma (MFH) and osteogenic sarcoma 
(Roessner, 1989; Apley and Solomon, 1993; Schajowicz, 
1994). Careful correlation of the microscopic 
appearances with the clinical and radiological findings is 
essential to avoid errors in diagnosis. 
Biological behaviour of GCT 
Although GCT is often considered to represent a 
"benign" primary osseous neoplasm, it rnay follow an 
aggressive and unpredictable clinical course and be 
difficult to treat effectively (Huvos, 1991; Unni, 1996). 
A considerable proportion of GCTs are locally 
aggressive at the time of presentation as  judged on 
clinical and radiological grounds. Radiological evidence 
of local aggression is  manifest by extensive bone 
destruction, cortical expansion and extension into 
surrounding soft tissue. Local recurrence is  also a 
significant management problem, with approximately 25 
to 35 % of GCTs recurring after simple curettage. 
Malignant or sarcomatous transformation is a rare 
complication of GCT. Sarcomatous change is usually 
believed to occur in a pre-existing GCT, often following 
previous irradiation. Examples of primary "de novo" 
malignant giant cell tumour of bone are recognised, but 
are  rare and much less  common than secondary 
malignant change. Histologically, sarcomatous change in 
GCT is  characterised by the identification of 
sarcomatous tissue associated with conventional GCT. 
The identification of areas of conventional GCT is 
critica1 to this diagnosis, to avoid confusion with other 
malignancies rich in giant  cells. The  sarcoma is  
identified on the basis of the presence of atypical mitotic 
figures and cytological anaplasia in the spindle cell 
mononuclear component. 
The development of pulmonary metastases is a rare 
but well documented phenomenon associated with 
conventional GCT of benign histology. Such pulmonary 
metastases or implants probably occur in no more than 
2% of patients,  and must be  distinguished from 
metastases arising from malignant giant cell tumours 
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(Vanel et al., 1983). The pulmonary metastases of 
histologically benign conventional GCT demonstrate the 
same morphology as the primary osseous lesion, and 
tend to have a relatively favourable prognosis, though 
this is not invariable and patients may succumb as a 
result of progressive growth of pulmonary lesions. 
Although some pulmonary deposits develop after 
surgical intervention, and may represent seeding of 
vessels as a result of surgical handling and curettage, 
others have been identified at the time of presentation 
and before any form of surgical intervention. In these 
circumstances, the metastases are possibly related to 
vascular invasion, a finding evident in a significant 
proportion of GCTs (Vanel et al., 1983; Wray et al., 
1990). 
In recognition that GCT may behave in a locally 
aggressive fashion or recur after surgical treatment, 
severa1 authors (Jaffe, 1940; Dahlin et al., 1970; 
Sanerkin, 1980; Fornasier et al., 1996) have attempted to 
identify histological features which might be predictive 
of local aggression and/or recurrence. Histological 
grading schemes however are generally regarded to be of 
limited value, as the presence of local aggression or 
recurrence does not appear to be related to any specific 
histological feature in conventional GCT. Although 
certain cellular characteristics were identified by 
histomorphometric study in GCT with more aggressive 
biological behaviour, this cumbersome tool has not yet 
applied to the point where it is clinically useful in 
predicting the biological behaviour of GCT (Fornasier et 
al., 1996). 
Severa1 biological factors have also been evaluated 
with respect to their prognostic significance. Some 
investigators have proposed that overexpression of c- 
myc (Gamberi et al., 1998) and urokinase plasminogen 
activator (Zheng et al., 1995) may be associated with the 
behaviour of GCT, but generally attempts to predict the 
neoplasm's aggressiveness using such parameters have 
largely been unsuccessful. In search of markers for 
biological behaviour of GCT, we analysed the gene 
expression of vascular endothelial growth factor (VEGF) 
and determined the prognostic value of its expression 
using Enneking's clinical stage at presentation as a 
parameter of "clinical/biological aggressiveness". We 
demonstrated that three isoforms of VEGF (121, 165 and 
189) were expressed in GCT but isoform 121 was the 
most abundant gene transcript (Zheng et al., 2000). 
Moreover, we have shown that the levels of VEGF gene 
expression correlated with Enneking's clinical staging. A 
relatively high leve1 of VEGF was gene expression, as 
detected by semi-quantitative RT-PCR, was found in 
stage 111 GCT than in the stage I/II. VEGF is expressed 
in spindle-shaped stromal-like tumour cells, round- 
shaped macrophage-like cells and osteoclast-like 
multinucleate giant cells. It is  possible that the 
production of VEGF by tumour cells and the induction 
of neoangiogenesis is part of tumour progression during 
the evolution of the neoplasm. The frequently 
incomplete, fenestrated endothelial barrier, in the newly 
formed tumour blood vessels, not only enables 
neoplastic celís to enter the circulation, but also assists 
blood monocytes migrating into the lesion. In fact, it was 
well appreciated by histological evaluation that GCT 
tumour cells are often situated within blood vessels (Fig. 
2). 
Histogenesis of GCT 
The precise histogenesis of GCT and the nature of 
its various cellular constituents have remained a matter 
of some controversy. Issues related to the histogenesis of 
GCT include questions such as: 1) do the multinucleate 
giant cells share a common ancestry with the 
mononuclear cells? 2) what biological significance can 
be attached to the co-existence of the various cell types 
in GCT? 3) what are the determinants of its biological 
behaviour? 4) does GCT originate from osteoclast 
lineage or stromal cell lineage? 
Flg. 2. Photomicrographs of giant cell tumour of bone. A. Typical 
histological features of GCT. Multinuclear giant cells are uniformly 
distributed throughout mononuclear cells. B. A blood vessel area in 
giant cell turnour of bone. Both stromal-like tumour cells (arrow) and 
osteoclast-like giant cells (arrow head) are present within blood vessels. 
Note that the multinucleate giant cells are probably present as the result 
of in situ formation of osteoclasts by the fusion of blood monocytes 
which have been activated by tumour cells, rather than the result of 
vascular invasion. x 400 
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ldentification of cell types in GCT 
Although the terms "Giant Cell Tumour" and 
'osteoclastoma' may imply that it is the multinucleated 
giant cells which are responsible for the proliferative 
capacity of the tumour, there is  evidence that the 
fibroblast-like stromal cells, the major component of the 
mononuclear cell  population, represent the true 
neoplastic component (Goldring et al., 1987; Doussis et 
al., 1992; Zheng et al., 1994, 1999). We, and others 
(Athanasou et al., 1985; Goldring et al., 1987; Feng, 
1990; Zheng et al., 1993, 1994), have previously shown 
that GCT consists of three major cell types. The first 
population, the spindle-shaped stromal mononuclear 
cells, proliferate well in culture and are the most likely 
candidate for the tumour's true neoplastic population. 
These cells phenotypically resemble connective tissue 
stromal derivatives, express no macrophage surface 
antigens, produce collagen types 1 and 111 and possess 
parathyroid hormone receptors (Goldring et al., 1987; 
Schajowicz, 1994; Zheng et al., 1994). In addition, these 
cells display cytogenetic aberrations including telomeric 
fusion, aneuploidy and chromosome deletion (Zheng et 
al., 1999). The second population of mononuclear cells, 
so called round-shaped macrophage-like cells, do not 
persist in long term culture and express monocyte- 
macrophage markers, such as CD68 antigen (Goldring et 
al., 1987; Schajowicz, 1994; Zheng et al., 1994). These 
macrophage-like cells account for 30% of the total cell 
population of GCT (Zheng et al., 1998). The third 
population of cells, the multinucleate giant cells, possess 
features of osteoclasts. These cells express calcitonin 
receptors, carbonic anhydrase 11, tartrate-resistant acid 
phosphatase and CD 68 antigen (Nicholson et al., 1987; 
Zheng et al., 1993, 1995, 1998) and are capable of 
resorbing bone in vitro (Zheng et al., 1993). These 
multinucleate cells, although detectable in early cultures, 
disappear after the first passage (Zheng et al., 1994). 
Ultrastructural studies have also confirmed that three 
distinct cell types exist in GCT (Steiner et al., 1972; 
Aparisi e t  al., 1977; Zheng e t  al., 1995). The 
mononuclear spindle-shaped tumour cells resemble 
fibroblastic cells at the ultrastructural level. They possess 
accentuated nuclear chromatin clumps along the nuclear 
envelope whereas the cytoplasm contains prominent 
endoplasmic reticulum, free ribosomes, and irregularly 
shaped mitochondria. Collagen fibres are often seen in 
the vicinity of these cells (Fig. 3). The ultrastructural 
features of the round mononuclear cells are similar to 
those of macrophages. The nuclei are oval with low 
Fig. 3. ldentification of cell types in giant cell tumour of bone. A. Ultrastructure of osteoclast-like giant cells. There are abundant mitochondria, vacuoles 
and lysosome-like bodies in the cytoplasm. x 6,500. B. Ultrastructure of round macrophage-like cells. The nucleus contains low density chromatin. 
There are numerous lysosomes, endoplasmic reticulums and free ribosomes. x 5,000. C. Ultrastructure of spindle-shaped stromal-like tumour cells. 
There is much heterochromatin along the nuclear membrane. The cytoplasm has membranes of granular endoplasmic reticulum and abundant free 
ribosomes. Collagen fibers are seen in the vicinity of cells. x 4,800 
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chromatin density. The cytoplasm is rich iri electron 
dense lysosomes, vesicles, well developed endoplasmic 
reticulum, Golgi apparatus, and free ribosomes (Fig. 3). 
The multinucleate giant cells appear morphologically 
similar to osteoclasts. They contain numerous nuclei of 
mostly oval shape. There are abundant mitochondria, 
distinct lysosome-like bodies, and large vacuoles in the 
cytoplasm (Fig. 3). In some instances, ruffled borders 
formed by finger-like projections of the cytoplasm have 
been seen. 
Multiple lines of evidence indicate that the fusion of 
round shaped macrophage-like cells (or their precursors) 
result in the formation of multinucleate osteoclast-like 
giant cells (Athanasou et al., 1985; Goldring et al., 1987; 
Zheng et al., 1993, 1994, 1998; Huang et al., 2000). In 
spite of the fact that the multinucleate giant cells are 
considered to be reactive osteoclasts, their 
morphological features, in particular their degree of 
multinucleation, differ somewhat from those of 
osteoclasts in normal bone. One possible explanation for 
this is that these syncytia are not found or formed in a 
normal bone microenvironment. Instead, as a result of 
sustained signalling of the rich cytokine environment 
generated by tumour cells, processes of cell fusion are 
enhanced resulting in the formation of large 
multinucleate giant cells. In fact, large multinucleate 
giant osteoclasts could always be observed in the case of 
normal osteoclast culture systems such as cultures of 
bone marrow cells (Suda et al., 1996), spleen cells or 
macrophage cell line RAW cells (Huang et al., 2000). 
The role of cytokines in GCT 
Osteolysis of cortical and trabecular bone within the 
lesion is undeniable evidence of a resorptive process that 
is mediated by the multinucleate osteoclast-like giant 
cells of GCT, but the mechanism by which this is 
achieved is not understood. It appears that the neoplastic 
cells (spindle-shaped stromal cells) of GCT produce 
cytokines that promote osteoclastogenesis and 
osteoclastic bone resorption. Our previous studies have 
shown that the neoplastic cells of GCT are capable of 
producing transforming growth factor-Bl (TGF-B1) 
which stimulates recruitment of reactive osteoclasts 
(Zheng et al., 1994). The osteoclast-like multinucleated 
giant cells express TGF-B type 11 receptor, further 
supporting a paracrine mechanism. Conditioned medium 
from tumour cell cultures established from GCTs have 
been shown to chemoattract osteoclasts and tartrate- 
resistant acid phosphatase-positive mononuclear cells 
(Zheng et al., 1994). Interestingly, administration of 
monoclonal antibodies against TGF-B1 only partly 
abolishes the chemotactic activity of the conditioned 
medium (Zheng et al., 1994). In search of other relevant 
cytokines that may enhance recruitment of reactive cells 
(especially those of CD68+ macrophage/osteoclast 
lineage) in GCT, we evaluated the presence of MCP-1 
gene transcript and protein in GCT and demonstrated 
that both MCP-1 gene transcript and MCP-1 protein 
were present in the cytoplasm of the stromal-like tumour 
cells of GCT (Zheng et al., 1998). Conditioned media 
from GCT cultures promoted the chemotactic migration 
of CD68+-peripherd monocytes, an activity which was 
abolished by the addition of MCP-1 antibody to the 
medium. Studies by others have also demonstrated that 
tumour cells of GCT produce TNF, interleukins-1, -6, 
-11, -17, and -18, M-CSF and PTHrP (Chambers et al., 
1985; Sasaguri et al., 1992; Mills et al., 1997; Atkins et 
al., 2000). In short, neoplastic cells of GCT are capable 
of recruiting monocytes, osteoclast precursor cells and 
even osteoclasts through the generation of various 
cytokines. 
It is noteworthy that although individual cytokines 
have direct andlor indirect role in the recruitment of 
osteoclasts and in osteoclast formation and bone 
resorption, none of these factors have been shown to 
directly induce macrophage-like cells to differentiate 
into osteoclasts. In fact, cells in other bone neoplasms 
such as osteosarcoma also express a similar cytokine 
profile (Andersen et al., 1998; Franchi et al., 1998; 
Mariani et al., 1998) as do those in GCT, but in these 
tumours much reduced degrees of osteoclast formation 
are observed. In search of other factors produced by the 
GCT neoplastic cells which may have the ability to 
generate osteoclast-like giant cells, possibly from 
recruited macrophage-like cells, we have identified that 
the ligand for receptor activator of NF-KB (RANKL), 
also known as osteoclast differentiation factor (ODF) 
(Yasuda et al., 1998), osteoprotegerin ligand (OPGL) 
(Lacey et al., 1998), and TNF-related activation-induced 
cytokine (TRANCE) (Anderson et al., 1997; Fuller et al., 
1998; Yasuda et al., 1998), as the factor necessary for the 
formation of the multinuclear osteoclast-like giant cells 
(Huang et d., 2000). 
RANKL is a member of the membrane-associated 
TNF-ligand family which directly regulates osteoclast 
differentiation and bone resorption (Anderson et al., 
1997; Simonet et al., 1997; Tsuda et al., 1997; Lacey et 
al., 1998; Yasuda et d., 1998). It has been shown, using 
in vitro culture system, that RANKL can both induce 
osteoclastogenesis and activate mature osteoclasts 
(Lacey et al., 1998; Yasuda et al., 1998). The expression 
of RANKL in osteoblast/stromal cells coincides with the 
formation of osteoclasts in co-cultures with bone marrow 
or spleen cell population. However, recombinant 
RANKL can replace the requirements for stromal cells 
in any in vitro model of osteoclastogenesis (Lacey et al., 
1998). Mice with a disrupted opgl gene completely lack 
osteoclasts as a result of the inability of osteoblasts to 
support osteoclastogenesis (Kong et al., 1999). The cell 
surface receptor that interacts with RANKL has been 
shown to be the ligand for the TNFR-related protein 
receptor activator of NF-KB (RANK) (Hsu et al., 1999). 
On the other hand, the decoy receptor of RANKL, OPG, 
also known as osteoclastogenesis inhibitory factor 
(OCIF) (Tsuda et al., 1997), has been shown to 
neutralize and interrupt stromal cell-derived RANKL- 
signals resulting in reduction of osteoclastogenesis 
Pathobiology of GCT 
(Simonet et al., 1997; Tsuda et al., 1997). Interestingly, 
OPG is a soluble member of the TNF-receptor family. 
We have shown that RANKL is abundantly 
expressed in stromal-like neoplastic cells of GCT 
whereas RANK, the receptor for RANKL, is expressed 
in macrophage-like cells and multinucleate osteoclast- 
like giant cells. Furthermore, the neoplastic cells of GCT 
are able to induce differentiation of RANK expressed 
myeloid RAW2 cells into osteoclast-like cells in the 
presence of I , ~ ~ o H ) ~ D ~  and dexamethasone (Huang et 
al., 2000). Thus, these findings strongly suggest that 
RANKL acts as an osteoclastogenesis-inducing factor 
linked to interaction between stromal like tumour cells 
and osteoclast progenitors in GCT. To summarise, GCT 
is a neoplasm of comective tissue stromal cells, which 
have the ability to recruit macrophage and multinucleate 
osteoclast-like giant cells. 
The role of steroid hormones in gient cell tumour of 
bone 
Given that steroid hormones play an important role 
in the maintenance of mineral homeostasis in bone 
through direct and indirect actions on osteoblasts and 
osteoclasts, it is  reasonable to assume that these 
hormones have some effect on the development and 
progression of GCT. Indeed, severa1 lines of clinical 
evidence suggest that the growth of GCT may be 
associated with steroid hormones. First, GCT has a 
marked female predilection in spite of the fact that most 
of the primary bone tumours are more common in males. 
Second, GCT has been reported to grow dramatically 
during pregnancy (Goldring et al., 1986). In particular, 
GCT in the pelvic bones may demonstrate unexpected 
and rapid growth during pregnancy (Goldring et al., 
1986; Komiya et al., 1999). Thirdly, GCTs have been 
shown to have a good therapeutic response to the 
administration of dexamethasone (Ziambaras et al., 
1997). It is noteworthy that the majority of these GCT 
patients who received dexamethasone therapy also had 
Paget's disease of bone (Jacobs et al., 1979; Potter et al., 
1991; Kim et al., 1997; Ziambaras et al., 1997). In a total 
of six cases reported in the literatures, administration of 
short-term, high-dose dexamethasone rapidly reduced 
the size of these tumours. However, discontinuation of 
the steroid treatment led to re-growth of the tumours in 
five of the six cases reported. 
In recognition of the role steroid hormones may play 
in the histogenesis of GCT, we and others have 
conducted a series of studies for the detection of 
receptors for oestrogen, glucocorticoid and vitamin Dg 
using in-situ hybridisation and RT-PCR techniques 
(Collier et al., 1998; Huang et al., 1999). It was found 
that both ERa and ERB mRNA are expressed in GCT 
and primary cultures of the neoplasm. ERB mRNA 
expression in GCT was negligible compared with 
osteosarcoma, suggesting that oestrogen receptor a (ER- 
a )  is predominantly expressed. Zn-situ hybridisation 
further confirmed that ER-a gene transcript is expressed 
in stromal-like tumour cells and macrophage-like cells 
but not in osteoclast-like giant cells. However, other 
investigators have indicated that it is the osteoclasts but 
not the neoplasmic cells of GCT that express ER 
receptors (Oursler et al., 1994). The inconsistency may 
be due to the purification of cells for RT-PCR analysis. 
The latter has used 90-95% pure preparation of 
osteoclast-like giant cells which may contain some 
tumour cells in the assay. In addition, nuclear binding 
Fig. 4. Representiitive katyotype of 
spindle-shaped mononuclear cells 
in giant cell turnour of bone. 
Telomeric fusion is observed 
between chromosornes 13p and 
10q. (Frorn: Zheng et al. Telorneric 
fusion is a major cytogenetic 
aberration of giant cell tumors of 
bone. Pathology 1999,31,373-378) 
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assay for oestrogen receptor showed that only one out of 
eleven cases of GCT have detectable oestrogen receptors 
in the solid tumour tissue (Wold et al., 1989). On the 
other hand, progesterone receptor proteins have been 
detected in GCT (Malawer et al., 1984). Taken together, 
GCT expresses both ER-a and progesterone receptors. 
Both clinical and laboratory evidence suggests that the 
tumour cells but not osteoclast-like giant cells are 
oestrogen target cells. 
We have also demonstrated that glucocorticoid 
receptor (GR) a and B, and Vitamin D3 receptor are 
expressed in GCT (Huang et al., unpublished data; 
Huang et al., 1999). The three major cell types seen in 
GCT i.e. stromal-like tumour cells, macrophage-like cell 
types and osteoclast-like giant cells al1 expressed both 
GRa and GRB as evidenced by in-situ hybridisation. 
Administration of dexamethasone stimulated the 
formation of osteoclast-like cells in GCT in the presence 
of 1,25 (OH)2D3. Furthermore, dexamethasone induced 
the production of RANKL but suppressed OPG in 
stromal-like neoplasmic cells of GCT (Huang et al., 
2000). 
Cytogenetics of GCT 
Various chromosomal aberrations have been reported 
in GCTs, including telomeric fusion, ring formation, 
translocations, marker chromosomes, deletions, double 
minutes, aneuploidy, polyploidy, telomeric reduction, 
chromosome and chromatid breaks, acentric 
chromosomes, dysenteric chromosomes, inversions, and 
premature chromatid separations (Noguera et al., 1989; 
Bridge et al., 1990, 1992; Schwartz et al., 1993, 1995; 
McComb et al., 1996; Zheng et al., 1999); however, the 
most consistently observed chromosome aberration in 
GCT is telomeric fusion (Fig. 4) (Bridge et al., 1992; 
Zheng et al., 1999). 
Telomeric fusion of speciñc chromosomes is a rare 
event involving the end-to-end joining of the ends of 2 or 
more chromosomes, without evidence or visible loss of 
genetic material from either of the chromosomes 
involved (Schwartz et al., 1995; McComb et al., 1996; 
Bridge et al., 1993; Harrison et al., 1994; Sawyer et al., 
1993; Pandita et al., 1996; Vagner-Capodano et al., 
1992; Kuwano et al., 1992; Meltzer et al., 1993; Schmitt 
et al., 1994). Telomeres are specialised structures, 
comprised of DNA and protein, capping the ends of 
eukaryotic chromosomes (Strachan and Read, 1996). 
Telomeres serve severa1 important functions. Telomeres 
maintain the structural integrity of a chromosome, 
preventing fusions, recombinations and degradations. 
Telomeres, through the activity of telomerase, also 
ensure the complete replication of the extreme ends of 
chromosome termini during celi division. 
Cytogenetics analyses of GCT (Bridge et al., 1992) 
have demonstrated that random chromosomal 
abnormalities were detected in 6 of the 10 tumours 
shown to be locally aggressive, recurrent or metastatic, 
and al1 but 1 of the 20 analysed yielded chromosomal 
abnormalities. Telomeric fusion, an unusual event, was 
the most striking random chromosomal aberration 
observed (Bridge et al., 1990). Telomeric fusion was 
observed in 14 of the specimens analysed, i.e. 70%, 
suggestive of a strong relationship between GCT and 
telomeric fusion. The most frequently involved 
telomeres were those on l lp ,  15p7 19q, 21p, 18p, 13p 
and 20q, in decreasing order of frequency (Bridge et al., 
1990, 1992). Our studies, however showed that the 
acrocentric chromosomes, especially chromosomes 13, 
14, and 21, were most commonly involved in telomeric 
fusion. Acrocentric chromosomes consist of very short p 
arms of indiscriminate length, comprised mainly of 
heterochromatin and possess satellites at the tips of the p 
arms (Rooney and Czepulkowski, 1992). The short arm 
almost appears to be an extension of the centromeric 
region and contains many short sequences of repetitive 
DNA (Rooney and Czepulkowski, 1992), which are 
susceptible to cytogenetic damage. It was the p arms of 
these acrocentric chromosomes which were most 
frequently fused (as was the case for al1 chromosomes). 
The one exception was chromosome 19, which was also 
commonly fused (Bridge et al., 1992), especially with 
chromosome 14. Interestingly, acrocentric chromosomes 
were often fused with other acrocentric chromosomes. 
Fusion of chromosomes 13 and 21 at the p arms was a 
frequent event, as was fusion of chromosomes 14 at the 
p arms, and chromosomes 15 and 21, also at the p arms 
(Bridge et al., 1992). The p arms of acrocentric 
chromosomes are generally more unstable and 
vulnerable to aberration than other chromosomes. This 
may be due to the short p arm having relatively small 
telomeres but possessing of satellites, which are 
commonly found to associate with the satellites of 
acrocentrics. Thus, these chromosomes may be more 
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biological behaviour of GCT. 
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susceptible to damage, such as telomenc fusion. 
Given telomeric fusion would imply a degree of 
genetic instability, such as that witnessed in many 
malignant neoplasms in which non-random telomeric 
fusion has been reported (Apley and Solomon, 1993), it 
may then serve as a potential precursor lesion to other 
abnormalities, such as translocations, aneuploidy and 
ring formation (Bridge et al., 1990; McComb et al., 
1996). Thus, telomeric fusion is considered to be the 
major cytogenetic alteration of GCT (Zheng et al., 
1999). It is not yet clear why telomeric fusions occur, or 
why some chromosomes are selectively affected in 
certain neoplasms. The prevalence of telomeric fusion in 
GCT suggests they may be a consequence of genomic 
instability induced during the neoplastic process (Apley 
and Solomon, 1993; Schwartz et al., 1995; Pandita et al., 
1996). 
Summary and Conclusion 
In conclusion, GCT is a primary benign neoplasm 
that produces expansile well delineated lytic lesions. The 
evidence indicates that it is a neoplasm of connective 
tissue stromal cells, which have the ability to recruit 
macrophage and multinucleate osteoclast-like giant cells. 
The neoplastic cells of GCT have various chromosomal 
aberrations. The  most consistently observed 
chromosome aberration was shown to be telomeric 
fusion. Perhaps dysfunctional telomeres may be crucial 
in GCT oncogenesis. A hypothetical model on the 
mechanism of histogenesis and the biological behaviour 
of GCT is presented in Fig. 5. As illustrated in the 
diagram, stromal-like tumour cells produce VEGF 
during progression of the neoplasm. This leads to the 
formation of incomplete vascular barriers (during 
angiogenesis) which provide a source of monocytes from 
the circulation. The latter are then recruited into the 
lesion by the local production of MCP-1 and TGF-B 
from the neoplastic cells. The tumour cells further 
stimulate the monocyte/macrophage toward the 
formation of osteoclast-like giant cells by the production 
of RANKL. Thus, three major cell types, the stromal- 
like neoplasmic cells, the macrophage-like cells and the 
multinuclear osteoclast-like giant cells al1 interact to 
form the lesion that characterises GCT of bone. 
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